Paperonium

Leukemia · Clin Cancer Res · 2012

The paper: chance would rarely make higher doses look this good. Its counts: chance easily could.

1 in 1001 in 1,0001 in 10,000every time1 in 20the usual barabout1 in 2,000The paper’s textabout6 in 10Its own counts
1 in 1001 in 1,0001 in 10,000every time1 in 20the usual barabout1 in 2,000The paper’s textabout6 in 10Its own counts

How often chance alone would produce a gap this big between dose groups

The paper says

On chemotherapy plus a new drug, 7 of 18 patients (39%) on its three higher doses went into remission, against 1 of 6 (17%) on the two lower. The paper reports p = 0.0005: chance alone would make that gap about 1 time in 2,000.

Its own data show

Its tables match. On those counts, the test the paper names gives p = 0.62: chance alone would make a gap this big about 6 times in 10. Even if all 8 remissions had been on the higher doses, p would be 0.066 (about 1 in 15). So 1 in 2,000 is out of reach.

A p-value is how often chance alone would produce a gap at least this big if dose made no difference. A group of 6 swings easily: one more remission there makes it 33% against 39%. A real dose gap would point to the new drug, since everyone got chemotherapy. These counts don’t show one. Its findings on safe doses stand.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias · Clin Cancer Res (2012) · doi:10.1158/1078-0432.CCR-12-2442